SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC

This study aims to evaluate the efficacy and safety of short-course radiotherapy combined with CAPOX plus bevacizumab with or without a PD-1 inhibitor in patients with locally advanced rectal cancer (LARC). The hypothesis is that the addition of immunotherapy (PD-1 inhibitor) can significantly improve the complete response (CR) rate and enhance local control while reducing the incidence of distant metastasis. This study will compare the effects of sequential chemoradiotherapy and targeted therapy with or without immunotherapy following short-course radiotherapy, aiming to explore the optimal r

Trial Details

NCT ID

NCT07198165

Phase

PHASE2

Sponsor

Ruijin Hospital

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

• PD-1 inhibitor based immunotherapy

Locations (sample)

• Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

• Histopathologically confirmed rectal adenocarcinoma with no prior antitumor therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →